



Ncyte IO Safety Panel

# Reliable Multi-Tissue Safety Screening Across Seven Human iPSC Models

The Ncyte IO Safety Panel gives early clarity on off-target or on-target off-tumour effects using seven human iPSC-derived tissues. You receive functional impedance data, an optional ICC-based target expression, and an IND-oriented report within ten weeks. A controlled, human-relevant way to derisk IO and ADC pipelines.

- ✓ Seven iPSC-derived human tissues in one workflow
- ✓ Functional toxicity readouts through impedance
- ✓ Target expression confirmed by ICC (optional)
- ✓ IND-aligned data package within ten weeks

7

human tissues screened in parallel

10

weeks from assay start to IND-oriented report

2

Readout types



Earlier human relevant safety data to support *in vivo*



The Ncyte IO Safety Panel captures cytotoxicity across neurons, cardiomyocytes, endothelial cells, alveolar epithelial cells, melanocytes, hepatocytes, and intestinal epithelial cells. This provides a clearer view of IO safety risks before animal studies or IND review.

Metric	Ncyte	Other Supplier
Cells per well	~40 percent less	Higher
Compounds per 100M cells	+60 percent	Lower
Reruns per 100 plates	Minimal	Multiple
Data continuity	Multi-year	Batch-to-batch variation

## Data Continuity & Quality

A single long-term batch keeps datasets aligned across months and years. This supports cleaner comparisons, smoother internal reviews, and stronger confidence during external evaluations. Stable input material reduces noise and improves the strength of your conclusions.

## Supporting Notes

- ✓ Functional and molecular validation completed across all key modalities
- ✓ Ten billion cell batch size
- ✓ Zero observed batch failure in current production scale

### Webinar:

Beyond binding – iPSC-based functional safety screening for oncology modalities

